ESR1 and breast neoplasm: Unlike breast tumors expressing ER and/or HER2, TNBCs generally do not respond to otherwise highly effective therapies such as selective estrogen receptor modulators (SERMs), like tamoxifen, raloxifene, and aromatase inhibitors that target the ER, or trastuzumab that targets HER2 expressing tumors [2].